Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.68 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.68 |
| ▸ | PRKDC | P78527 | 1/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.46 |
| ▸ | HTR3B | O95264 | 4/20 | 0.46 |
| ▸ | HTR3A | P46098 | 4/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30826872 | 0.94 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL27263501 | 0.94 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL27261193 | 0.87 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL30826767 | 0.86 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL7039585 | 0.85 | PIK3CD (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL18493255 | 0.85 | PRKDC (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL11297084 | 0.83 | PIK3CD (0.71) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL30826741 | 0.81 | PRKDC (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL27262618 | 0.81 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL31494973 | 0.81 | CHRNB2 (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064026-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024064026-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-7569337-B2 | Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| EP-1483262-B1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | disclosed |
| EP-1483262-A1 | COUMARINES USEFUL AS BIOMARKERS | Novartis AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074519-A1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | CCNB1, CBR1, CYP1A1 | PIK3CD 4159/4885PIK3CA 2439/4885PIK3CB 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.